Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development

Asahi Kasei Bioprocess America, Inc (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics. The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility spanning an area of 59,000 square feet (approximately 5,481 square meters) in Berlin. This cooperation aims to […]

QIAGEN receives approval for NeuMoDx HIV-1 Quant assay in Thailand for blood-borne virus testing

QIAGEN announced that its NeuMoDx human immunodeficiency virus type 1 (HIV-1) assay has received approval for use in Thailand. Along with the previously approved hepatitis B virus (HBV) and hepatitis C virus (HCV) quantitative assays there is now a full complement of blood-borne virus (BBV) assays available in Thailand. Every day, millions of patients infected […]

Poor Laboratory Inventory Management & Its Ripple Effect

Inventory management happens to be simultaneously the most essential and, at the same time, the most disliked task that laboratorians carry out on a daily basis. But poor inventory management goes on to virtually impact every facet of the lab. Lab elements that are affected by poor inventory management Research Efficiency, Accuracy, As Well As […]

Better Flexible Lab Design Space Is An Option To Look Into

Life science companies happen to be facing either a rapid expansion or a consolidation because of the fluctuations in market conditions, the requirement to adapt to new processes with rapidly advancing technology, and the rising demands of speed-to-science, with an accelerated demand to get the medicines as well as the therapies faster from bench to […]

Advancements In Drug Delivery Strengthen Health of Women

Right from elevating the contraceptive methods to going ahead and improving the treatment of reproductive health issues, drug delivery innovations happen to be paving the way for a more personalized as well as an effective approach to women’s healthcare. Numerous innovations, such as nanotechnology as well as biomaterial-based drug delivery technologies, happen to be addressing […]

Drug Delivery – Switchable Peptide-Stabilized Emulsions

A new study which has been led by Prof. Meital Reches from the Hebrew University, along with Mr. Daniel Boas, one of the Ph.D. students in her group, as well as the team of collaborators, has gone on to pioneer a new drug delivery system that happens to be centered on switchable peptide-stabilized emulsions. This […]

Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY can help to close the treatment gap in osteoporosis

UCB, a global biopharmaceutical company announced key findings from the first retrospective patient cohort study in Denmark to observe the characteristics of patients selected for romosozumab treatment in routine clinical practice. The data were presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2024 in London. The observational, […]

Cell & Gene Therapies: FDA Regulatory Considerations In 2024

The fact is that most in the biotech industry know that cell and gene therapies- CGT are regulated across the U.S. as biological products by the FDA’s Center for Biologics Research and Evaluation- BER and need approval of a biologics license application- BLA under Section 351 of the Public Health Service Act before being marketed. […]

Can Clinical Research Spectrum Make The Most of Gene Therapy

It is a well-established fact that gene therapy research happens to be booming. Since the U.S. Food and Drug Administration- FDA issued its first approval when it comes to gene therapy in 2017, oncology researchers have gone on to be breaking barriers as far as gene therapy trials are concerned, which was then followed by […]

US Enacts Biosecurity Law Blocking Chinese Bio Company Deals

In March 2024, one of the biosecurity laws restricting transactions with Chinese bio companies happened to pass the U.S. Congress, and now the global contract development and production- CDMO companies happen to be trying to secure production facilities within the U.S. This is because of the concerns that bio could as well be the next […]